The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China

References

• Wang JX, Huang XJ, Wu DP, et al. [Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China]. Zhonghua Xue Ye Xue Za Zhi 2009;30:721-5
   PubMedGoogle Scholar
• He QT, Shi FT, Yuan ZZ. Epidemiological investigation of leukemia in Baotou. Inner Mongolia Med J 1993;2:3-5
   Google Scholar
• Hu JL, Mao Z, Dong DP, et al. Epidemiological investigation of leukemia in 15 years in Haian County. Chin Med J Commun 2004;18:114-15
   Google Scholar
• Tang ZX, Sun QY, Zhang JT, et al. Epidemiological investigation of leukemia in 11 years in the Jinshan district of Shanghai. Zhonghua Xue Ye Xue Za Zhi 1994;15:430
   Google Scholar
• Zhang XY, Zhang DL, Sun X, et al. Epidemiological investigation of leukemia and aplastic anemia in Shenzhen. Zhonghua Xue Ye Xue Za Zhi 2001;22:347
   Google Scholar
• Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009;23:602-4
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemo Res Prac 2014;Article ID 357027:1-9. http://dx.doi.org/10.1155/2014/357027 Accessed on 29 September 2016
   Google Scholar
• Jiang Q, Huang X. CML treatment and development in China. Chin J Intern Med 2013;52:803-5
   PubMedGoogle Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-65
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84
   PubMed Web of Science ®Google Scholar
• Oriana C, Martin H, Toby P, et al. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value Health 2013;16:1081-90
   PubMed Web of Science ®Google Scholar
• Szanto A, Pap Z, Benedek I, et al. Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center. Rom J Morphol Embryol 2013;54:37-42
   PubMed Web of Science ®Google Scholar
• NICE. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241). NICE; London. 2012. http://www.nice.org.uk/guidance/ta241 Accessed on 29 September 2016
   Google Scholar
• Marum JE, Branford S. Current developments in molecular monitoring in chronic myeloid leukemia. Ther Adv Hematol 2016;7:237-51
   PubMedGoogle Scholar
• Goldberg SL, Chen L, Guerin A, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin 2013;29:1075-82
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CMA. [Guideline for management of chronic myeloid leukemia (2016)]. Zhonghua Xue Ye Xue Za Zhi 2016;37:633-9
   PubMedGoogle Scholar
• Chen L, Guerin A, Xie J, et al. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin 2012;28:1831-9
   PubMed Web of Science ®Google Scholar
• Oncology Patient Assistance Programs. Novartis Global. https://www.novartis.com/about-us/corporate-responsibility/access-healthcare/global-access-programs/oncology-patient Accessed on 29 September 2016
   Google Scholar
• Guerin A, Chen L, Dea K, et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ 2014;17:89-98
   PubMedGoogle Scholar
• Introduction. The First Affiliated Hospital of Soochow University Suzhou First People’s Hospital. Suzhou, China. http://fyy.sdfyy.cn/Main/Display_B721_A0.html Accessed on 29 September 2016
   Google Scholar
• NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. London. 2009. http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf Accessed on 29 September 2016
   Google Scholar
• Tao Z, Liu B, Zhao Y, et al. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib. Leuk Res 2014;38:1030-5
   PubMed Web of Science ®Google Scholar
• Darkow T, Maclean R, Joyce GF, et al. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. Am J Manag Care 2012;18:S272-S8
   Google Scholar
• Chen Z, Wang C, Xu X, et al. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health 2009;12(Suppl 3):S85-S8
   Google Scholar
• Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-102
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-42
   PubMed Web of Science ®Google Scholar
• Palandri F, Iacobucci I, Soverini S, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res 2009;15:1059-63
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou J, Jiang D, et al. The application of monitoring bcr/abl fusion gene in the therapy of chronic myeloid leukemia. J Leuk Lymph 2004;13:82-4
   Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
   PubMed Web of Science ®Google Scholar
• Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. DOI: 10.1200/JCO.2016.68.2914 Journal of Clinical Oncology - published online before print October 31, 2016
   Google Scholar